UPPER TRACT UROTHELIAL CANCER (UTUC)

UroGen Pharma Reports Fourth Quarter and Full-year 2021 Financial Results and Recent Corporate Developments

Retrieved on: 
Monday, March 21, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Private Securities Litigation Reform Act, Risk, Adult, Fatigue, SEC, Urination, Cancer, Medicine, Neoplasm, Breast milk, Sodium bicarbonate, Technology, Twitter, UTUC, Patient Information Advisory Group, Trial of the century, Time, NDA, Ureter, Urine, Recurrence, Transitional cell carcinoma, Kidney, Nausea, Pain, View, Clothing, Perforation, Swelling, Female, Nephrectomy, Vomiting, NMIBC, Clinical trial, Growth, Urinary tract infection, Man, Urinary bladder, FDA, Patient, Birth, Abdomen, Company, Stomach, ATLAS, Skin, Bone marrow, Fever, Safety, Orphan drug, COVID-19, Arm, Transitional epithelium, Blood, TURBT, Water, Pharmaceutical industry, Medical imaging, Health insurance, Birth control, Tanning (leather), Phosphorus, Generic drug, Mitomycin C, Mitomycins, JELMYTO®, UPPER TRACT UROTHELIAL CANCER (UTUC), UGN-102, THE PHASE 3 ENVISION TRIAL, THE PHASE 3 ATLAS TRIAL, UROGEN PHARMA LTD., JELMYTO®, UPPER TRACT UROTHELIAL CANCER (UTUC), UGN-102, THE PHASE 3 ENVISION TRIAL, THE PHASE 3 ATLAS TRIAL, UROGEN PHARMA LTD.

The U.S. FDA previously granted Orphan Drug, Fast Track, and Breakthrough Therapy Designations to Jelmyto for the treatment of LG-UTUC.

Key Points: 
  • The U.S. FDA previously granted Orphan Drug, Fast Track, and Breakthrough Therapy Designations to Jelmyto for the treatment of LG-UTUC.
  • You should not receive JELMYTO if you have a hole or tear (perforation) of your bladder or upper urinary tract.
  • Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with JELMYTO.
  • JELMYTO and UroGen are registered trademarks of UroGen Pharma Ltd.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20220321005260/en/

UroGen Pharma Reports Third Quarter 2021 Financial Results and Recent Corporate Developments

Retrieved on: 
Monday, November 15, 2021
Biotechnology, Pharmaceutical, Health, TURBT, Urine, Bone marrow, Cancer, Female, Clinical trial, Swelling, Nephrectomy, Growth, COVID-19, Urinary tract infection, Perforation, Pain, Solution, Transitional epithelium, ATLAS, Safety, Abdomen, Kidney, Recurrence, Patient Information Advisory Group, Technology, Blood, Transitional cell carcinoma, Probability, Ureter, Vomiting, Fever, Fatigue, Clothing, Patient, FDA, Adult, Bladder cancer, View, Private Securities Litigation Reform Act, Medicine, Orphan drug, Breast milk, Risk, Twitter, UTUC, Urinary bladder, SEC, Urination, Man, Nausea, Sodium bicarbonate, Arm, Water, Birth, Stomach, Neoplasm, Company, Skin, Pharmaceutical industry, Medical imaging, Health insurance, Birth control, Tanning (leather), Phosphorus, Generic drug, Jelmyto®, Upper Tract Urothelial Cancer (UTUC), UGN-102, the Phase 3 ATLAS Trial, UroGen Pharma Ltd., JELMYTO®, UPPER TRACT UROTHELIAL CANCER (UTUC), UGN-102, THE PHASE 3 ATLAS TRIAL, UROGEN PHARMA LTD.

The U.S. FDA previously granted Orphan Drug, Fast Track, and Breakthrough Therapy Designations to Jelmyto for the treatment of LG-UTUC.

Key Points: 
  • The U.S. FDA previously granted Orphan Drug, Fast Track, and Breakthrough Therapy Designations to Jelmyto for the treatment of LG-UTUC.
  • You should not receive JELMYTO if you have a hole or tear (perforation) of your bladder or upper urinary tract.
  • Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with JELMYTO.
  • JELMYTO and UroGen are registered trademarks of UroGen Pharma Ltd.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20211115005427/en/

 UroGen Pharma Reports Second Quarter 2021 Financial Results and Recent Corporate Developments

Retrieved on: 
Wednesday, August 4, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Chemical compounds, Health sciences, Organic compounds, Orphan drugs, Breakthrough therapy, Aziridines, Cancer treatments, Mitomycin C, Oncology, Fast track, Jelmyto®, Upper Tract Urothelial Cancer (UTUC), UGN-102, the Phase 3 ATLAS Trial, UroGen Pharma Ltd., JELMYTO®, UPPER TRACT UROTHELIAL CANCER (UTUC), UGN-102, THE PHASE 3 ATLAS TRIAL, UROGEN PHARMA LTD.

The U.S. FDA previously granted Orphan Drug, Fast Track, and Breakthrough Therapy Designations to Jelmyto for the treatment of LG-UTUC.

Key Points: 
  • The U.S. FDA previously granted Orphan Drug, Fast Track, and Breakthrough Therapy Designations to Jelmyto for the treatment of LG-UTUC.
  • You should not receive JELMYTO if you have a hole or tear (perforation) of your bladder or upper urinary tract.
  • Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with JELMYTO.
  • JELMYTO and UroGen are registered trademarks of UroGen Pharma, Ltd.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210804005328/en/

UroGen Pharma Announces License and Supply Agreement with Neopharm to Pursue Regulatory Approval and Commercialization for Jelmyto® in Israel

Retrieved on: 
Wednesday, July 28, 2021
Biotechnology, Pharmaceutical, Health, Oncology, Chemical compounds, Organic compounds, Heterocyclic compounds, Aziridines, Breakthrough therapy, Mitomycin C, Oncology, Quinones, Jelmyto®, Upper Tract Urothelial Cancer (UTUC), UroGen Pharma Ltd., Neopharm, JELMYTO®, UPPER TRACT UROTHELIAL CANCER (UTUC), UROGEN PHARMA LTD., NEOPHARM

We are proud to be the first company outside the US to have started the regulatory approval and commercialization process for Jelmyto, demonstrating Israel's importance in geographic expansion.

Key Points: 
  • We are proud to be the first company outside the US to have started the regulatory approval and commercialization process for Jelmyto, demonstrating Israel's importance in geographic expansion.
  • I am confident that our well-established expertise and heritage of collaboration with innovative biopharmaceutical companies will make Jelmyto a success in Israel.
  • UroGen is committed to bringing the promise of Jelmyto to as many patients as possible, as quickly as feasible.
  • JELMYTO and UroGen are registered trademarks of UroGen Pharma, Ltd.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210728005968/en/

UroGen Pharma Reports Strong Preliminary Jelmyto® Sales for Second Quarter 2021

Retrieved on: 
Wednesday, July 14, 2021
Oncology, Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Chemical compounds, Organic compounds, Clinical medicine, Brand management, Brands, Intellectual property law, Product management, Trademark, Mitomycin C, Jelmyto®, Upper Tract Urothelial Cancer (UTUC), UroGen Pharma Ltd., JELMYTO®, UPPER TRACT UROTHELIAL CANCER (UTUC), UROGEN PHARMA LTD.

Additionally, operating expenses in the second quarter of 2021 are anticipated to be in the range of $33 to $38 million.

Key Points: 
  • Additionally, operating expenses in the second quarter of 2021 are anticipated to be in the range of $33 to $38 million.
  • We look forward to reporting our full results for the second quarter of 2021 in early August.
  • The Company expects to report full financial results for the second quarter ended June 30, 2021, and host a conference call on Wednesday, August 4, 2021.
  • JELMYTO and UroGen are registered trademarks of UroGen Pharma, Ltd.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210714005260/en/

UroGen Pharma Reports First Quarter 2021 Financial Results and Recent Corporate Developments

Retrieved on: 
Thursday, May 13, 2021
Oncology, Health, Hospitals, Other Health, Pharmaceutical, Biotechnology, Health sciences, Pharmacology, Health, Breakthrough therapy, Orphan drugs, Antineoplastic drugs, Aziridines, Enones, Mitomycin C, Hydrogel, Fast track, Modified-release dosage, Jelmyto®, Upper Tract Urothelial Cancer (UTUC), UGN-102, the Phase 3 ATLAS Trial, UroGen Pharma Ltd., JELMYTO®, UPPER TRACT UROTHELIAL CANCER (UTUC), UGN-102, THE PHASE 3 ATLAS TRIAL, UROGEN PHARMA LTD.

The U.S. FDA previously granted Orphan Drug, Fast Track, and Breakthrough Therapy Designations to Jelmyto for the treatment of LG-UTUC.

Key Points: 
  • The U.S. FDA previously granted Orphan Drug, Fast Track, and Breakthrough Therapy Designations to Jelmyto for the treatment of LG-UTUC.
  • It is important that you receive all 6 doses of JELMYTO according to your healthcare provider\xe2\x80\x99s instructions.
  • If you miss any appointments, call your healthcare provider as soon as possible to reschedule your appointment.
  • UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs.